Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 69 for “"ibrutinib"”.
-
Real-World Bleeding with Ibrutinib in B-Cell Malignancies
Ibrutinib is used to treat B-cell malignancies. Bleeding occurred in up to 50% of ibrutinib-treated clinical trial participants, but major bleeding was uncommon. However, trials excluded patients with certain risk factors and may underestimate major bleeding frequency in clinical practice. …
-
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
Ibrutinib serves as an efficient second-line therapy in relapsed/refractory mantle cell lymphoma. However, resistance to the BTK inhibitor results in a poor prognosis for patients. Since the mechanisms leading to resistance in initially responding tumor cells are poorly understood, this work aimed …
-
Ibrutinib as a potential therapeutic option for HER2+ breast cancer – the role of STAT3 and p21
… therapeutic options in the treatment of cancers. Ibrutinib (Imbruvica), an FDA approved tyrosine kinase inhibitor (TKI) for BTK, has shown to be effective in HER2 overexpressing breast cancer cell lines. However, the exact mechanism of action of ibrutinib in HER2 overexpressing breast cancer …
-
Real-world characterization of ibrutinib therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma in British Columbia
Background: Ibrutinib therapy has quickly become standard of care in Canada for CLL/SLL patients, due to its proven survival benefits. Real-world studies, however, have unveiled that ibrutinib therapy is also associated with higher rates of discontinuations and toxicities in patients. It is …
-
DEVELOPMENT OF AN AMORPHOUS BASED SUSTAINED RELEASE TABLET OF MELT EXTRUDED IBRUTINIB A BRUTON’S TYROSINE KINASE INHIBITOR
Ibrutinib is the first Bruton`s tyrosine kinase (BTK) inhibitor for oral administration approved by FDA in 2014. It is the first-line treatment for B-cell malignancies, which are the most common hematologic neoplasia. Ibrutinib is a relatively safe alternative for currently used treatment …
-
Μελέτη της επίδρασης του φαρμάκου Ibrutinib, αναστολέα της τυροσινικής κινάσης Bruton, στην in vitro λειτουργικότητα αιμοπεταλίων ασθενών
… από τους διάφορους υποδοχείς τους. Το Ibrutinib, αναστολέας της BTK, ενδείκνυται για τη θεραπεία των Β-λεμφοϋπερπλαστικών νοσημάτων. Το Ibrutinib συνδέεται με αυξημένο κίνδυνο αιμορραγίας και υπάρχουν ενδείξεις που υποδηλώνουν ότι μπορεί να οφείλεται σε δυσλειτουργία των αιμοπεταλίων …
-
The impact of cost sharing on adherence to ibrutinib for patients with diffuse large B-cell lymphoma
Purpose: Nonadherence with ibrutinib, an oral treatment for diffuse large B-cell lymphoma (DLBCL), has been associated with disease progression. We examined the relationship between out-of-pocket (OOP) ibrutinib costs and adherence to ibrutinib among new users with DLBCL. Patients and Methods: We …
-
Development and characterization of a novel model of ibrutinib resistance in Chronic Lymphocytic Leukemia (CLL) that displays sensitivity to PI3K inhibition
… promoting cell survival. The BTK inhibitor ibrutinib revolutionized CLL treatment; unfortunately, resistance is now on the rise, creating the need for a better understanding of the effects of long-term ibrutinib use. This project aims to establish and characterize a cell line model of …
-
Preclinical Evaluation of Synergistic Drug Combinations in Acute Myeloid Leukemia
… Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has significantly improved patient outcomes in B-cell malignancies, where BTK signaling is implicated in disease progression. Documented expression of constitutively active BTK in AML cells has generated interest in evaluating the …
-
Antihistamines induce synergistic cell death when combined with ibrutinib in malignant B cell lines and primary chronic lymphocytic leukemia cells
… when combined with the tyrosine kinase inhibitor ibrutinib. This synergistic cell death was found to occur through an increase in intracellular reactive oxygen species, mitochondrial dysfunction, and degradation of the anti-apoptotic protein Mcl-1. Taken together, this study proposes to repurpose …
-
The effect of Btk inhibition on platelet activation by GPVI and CLEC-2
Background: The novel Btk inhibitor ibrutinib has recently been introduced into the clinic for treatment of lymphoproliferative disorders (LPDs) where it is unexpectedly associated with major bleeding. It has been shown to block GPVI and CLEC-2-mediated platelet function with the former correlating …
-
Investigating the role of BTKi and the histone variant macroH2A1 in chronic lymphocytic leukaemia
… shift in CLL treatment. BTK inhibition by Ibrutinib has been associated with changes at the epigenetic level and shown to alter the CLL enhancer landscape.<br/><br/>A MACROH2A1-related Ibrutinib-responsive active region was discovered in matched pre-/post-Ibrutinib treated CLL samples by …
-
ZIPK mediates pre-mRNA processing in chronic lymphocytic leukaemia via histone H3 threonine 6 and threonine 11 phosphorylation
… modifications are repressed by ibrutinib, a small molecule inhibitor used in CLL treatment. DAPK inhibition mimics Ibrutinib-induced repression of both IEG mRNA and histone H3 phosphorylation, and has anti-proliferative effects comparable to ibrutinib on CLL cells in vitro. DAPK …
-
B cell receptor activation and effect of kinase inhibitors in CLL
… of B cell malignancies and autoimmune disorders. Ibrutinib (BTK inhibitor) and Idelalisib (PI3K-δ inhibitor) are the first-in-class of these subsets of drugs. These drugs have changed the treatment landscape of CLL. IciCLLe trial was an endeavour to assess the clinical, immunophenotypic and …
-
QUANTITATIVE PROTEOMIC APPROACHES TO STUDY DRUG MECHANISM OF ACTION
… order to study covalent mechanism of action of ibrutinib, a covalent inhibitor of the tyrosine protein kinase BTK, approved by FDA in 2013 for the treatment of B cell malignancies. We used ibrutinib as case study, but the developed protocols can be applied to the study of other covalent …
-
The role of histone kinases in controlling transcription in B cell lymphoma and leukaemia
… this project aimed to understand the effects of Ibrutinib on chromatin structure in chronic lymphocytic leukaemia (CLL) cells. Ibrutinib inhibits Bruton’s tyrosine kinase, and thus B cell receptor (BCR) signalling, and is currently being tested in clinical trials for the treatment of CLL. In …
-
Atrial Electrophysiology and Arrhythmogenesis: Impacts of Diabetes Mellitus and Bruton's Tyrosine Kinase Inhibitors
… Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, used in the treatment of B-cell lymphomas, also leads to new-onset AF in patients; however, a thorough investigation of the effects of BTK inhibitors on atrial electrophysiology has not been conducted. BTK inhibition can modulate similar …
-
Identification of pharmacological vulnerabilities in drug-resistant melanoma cells
… compound that we identified in this analysis was ibrutinib, which is clinically used as a BTK inhibitor. Interestingly, we found that ibrutinib does not reverse BRAFi resistance through BTK inhibition, but rather through the polypharmacology of the compound. The differentially expressed genes in …
Page 1 of 4